Averin Capital Acquisition Corp. prices IPO at $10 per unit, set to trade on Nasdaq starting February 19, 2026.
Quiver AI Summary
Averin Capital Acquisition Corp. announced the pricing of its initial public offering (IPO) of 25,000,000 units at $10.00 per unit, set to trade on Nasdaq under the symbol "ACAAU" beginning February 19, 2026. Each unit includes one Class A ordinary share and one-sixth of a redeemable warrant, with the warrants allowing the purchase of shares at $11.50 each. The offering is expected to close on February 20, 2026, subject to customary conditions, and includes an option for underwriters to purchase an additional 3,750,000 units. The company, led by CEO David A. Berry, will focus on acquiring businesses in technology and health industries. Deutsche Bank Securities Inc. is the sole book-running manager for the offering. The press release also includes a disclaimer about forward-looking statements and legal conditions regarding the securities.
Potential Positives
- Averin Capital Acquisition Corp. has successfully priced its initial public offering (IPO) of 25,000,000 units at $10.00 per unit, indicating strong investor interest and the ability to raise substantial capital.
- The IPO units will begin trading on Nasdaq under the ticker symbol "ACAAU," enhancing the company’s visibility and credibility in the market.
- The offering includes a provision for underwriters to purchase an additional 3,750,000 units, which could provide further capital and indicate confidence from the underwriting team.
- The company’s focus on acquiring opportunities in technology and health industries aligns with growth sectors, positioning it well for potential future success.
Potential Negatives
- The press release includes a disclaimer that the offering may not be completed on the terms described, or at all, indicating uncertainty for investors.
- The mention of forward-looking statements implies potential risks and uncertainties that may affect the success of the IPO and subsequent business combinations.
- As a blank check company, there is inherent risk associated with the lack of a targeted acquisition at the time of the IPO, which may deter some investors.
FAQ
What is the price of Averin Capital's initial public offering?
The initial public offering price is set at $10.00 per unit.
When will Averin Capital's units begin trading on Nasdaq?
The units are expected to begin trading on February 19, 2026.
What does each unit consist of in the IPO?
Each unit consists of one Class A ordinary share and one-sixth of a redeemable warrant.
How many units can the underwriters purchase for over-allotments?
The underwriters can purchase up to an additional 3,750,000 units to cover over-allotments.
What industries does Averin Capital plan to focus on for acquisitions?
Averin Capital expects to focus on acquisition targets in technology and health industries.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
New York, NY, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Averin Capital Acquisition Corp. (the “Company”) announced today the pricing of its initial public offering of 25,000,000 units at a price of $10.00 per unit. The units are expected to be listed on the Nasdaq Global Market (“Nasdaq”) and begin trading on February 19, 2026, under the ticker symbol “ACAAU.” Each unit consists of one Class A ordinary share and one-sixth of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. An amount equal to $10.00 per unit will be deposited into a trust account upon the closing of the offering. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “ACAA” and “ACAAW,” respectively. The offering is expected to close on February 20, 2026 subject to customary closing conditions. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,750,000 units at the initial public offering price to cover over-allotments, if any.
The Company is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company may pursue an acquisition opportunity in any business or industry but expects to focus on a target in technology and health industries.
The Company’s management team is led by David A. Berry, the Chairman and Chief Executive Officer, and Alex Lau, its Chief Financial Officer and Secretary. The Board of Directors also includes Ulrik Schulze, Graeme Bell, and Mary T. Szela.
Deutsche Bank Securities Inc. is acting as sole book-running manager for the offering.
The offering is being made only by means of a prospectus. When available, copies of the prospectus may be obtained from Deutsche Bank Securities Inc., Attention: Capital Markets, 1 Columbus Circle, New York, New York 10019, or by email at [email protected] or by accessing the SEC’s website, www.sec.gov.
A registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective on February 18, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements
This press release contains statements that constitute “forward-looking statements,” including with respect to the expected closing of the proposed initial public offering and search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all.
Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the “Risk Factors” section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC. Copies of these documents are available on the SEC’s website, www.sec.gov . The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Investor Contacts
Averin Capital Acquisition Corp.
David Berry, Chief Executive Officer
[email protected]